Benztropine Mesylate NDC 67046-0040

NDC codes

FDA NDC Directory

Product NDC (as listed)67046-0040Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67046-0040Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
67046-0040-3	67046004003	30 TABLET in 1 BLISTER PACK (67046-0040-3)Marketed from May 26, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Benztropine Mesylate
Generic name (nonproprietary): benztropine mesylate
Active ingredients: Benztropine mesylate — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Coupler LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040715
Marketing start: May 26, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cholinergic Antagonists (Mechanism)Histamine Receptor Antagonists (Mechanism)
Identifiers: Product ID 67046-0040_52bd799d-8da4-d684-e063-6294a90a396eSPL ID 52bd799d-8da4-d684-e063-6294a90a396eSPL set ID 52bd605a-6a28-c2ec-e063-6294a90a8371RxCUI 885209UNII WMJ8TL7510
Pharmacologic class: Anticholinergic; Antihistamine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467046004003 followed by a unit qualifier and the quantity

Package 67046-0040-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 26, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)